NASDAQ
76.41USD
+6.43 (+9.20%)
We have scored 55 news catalysts on Tempus AI, Inc. (TEM) over the past 12 months. The biggest single-day move next to one of them came Sep 17, 2026, when TEM closed +14.0%: “Tempus AI Is Ripping 30% Higher This Week After Morgan Stanley Boosts Revenue Outlook”. Coverage across the window leans positive (average ticker sentiment +0.51). Most of the impact sits in sector healthcare and sector technology.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
14B
P/E
—
EPS
—
Beta
3.72
52W range
40.77-104.32
Day range
72.62–76.73
Open
72.70
Prev close
69.97
Volume
1.8M
Avg volume
6.6M
Dividend
0.00
IPO
2024-06-14
Analysts publish price targets on TEM, and they disagree. Where the share price actually sits among them shows which of their arguments the market is buying — and which it is ignoring.
11 analyst price targets from $50 to $80
as of 2026-09-14
The market is 12% below the median target — more cautious than the analysts.
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Tempus AI, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Suppliers, customers, partners and competitors of Tempus AI, Inc., taken from what the news actually said about them rather than from a sector bucket. The count is how many articles established each link.
Latest scored catalyst for TEM: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sciences and advanced precision research; diagnostics services, such as NGS diagnostics, PCR profiling, and other anatomic and molecular pathology tests; and large-panel solid tumor and hematologic testing through multiple assays, with its core clinical assay (xT and xR) offering large panel DNA, RNA full transcriptome, and incidental germline findings through normal blood or saliva analyses. In addition, it provides genetic tests focused on inherited conditions; an nP assay for pharmacogenomic testing for patients with psychiatric conditions, including depression, general anxiety disorder, bipolar disorder, and other relevant diagnoses; Insights, which licenses libraries of linked, de-identified clinical, molecular, and imaging data; Organoids, a tumor derived biological modeling. Further, the company offers Trials for clinical trial matching services; Next, an AI platform; Algos, an algorithm-based diagnostics application. It has Strategic Collaborations with AstraZeneca AB, Pathos AI, Inc., GlaxoSmithKline, Merck, and Recursion Pharmaceuticals, Inc. Additionally, it also has a strategic collaboration with Blood Cancer United to develop registry for pediatric acute myeloid leukemia. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.
The reconstruction
At $76.41, the stock sits at the 27th percentile of published models and 12% below the median $67 target, meaning the market accepts the near-term diagnostics growth story but refuses to pay for the full AI-platform upside that bulls project.
What the disagreement turns on
Does the Data and Applications segment actually accelerate revenue and margin expansion enough to justify a premium valuation, or does the company remain an unprofitable diagnostics business? The available data can measure unit volume growth in the segment but cannot measure pricing power, adoption, or margin impact directly.
The price pays for
It declines to pay for
Written by a language model from the published models, the reported segments and a reverse-DCF — not a recommendation, and not a house view.
Claim by claim
Computed at $59.01 on 2026-09-14 — the quote has since moved +29%, so read this as a record of what was priced in then, not now.
